HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach Confirmation Clears Holds At Tail-End Of Lame Duck

This article was originally published in The Tan Sheet

Executive Summary

Andrew von Eschenbach's nomination to be FDA commissioner cleared the Senate by a comfortable 80-11 margin on Dec. 7, ending months of "holds" on the vote and opposition from both sides of the aisle

You may also be interested in...



Election 2008: Both Candidates Are Likely To Change FDA’s Direction

Whether Illinois Democrat Sen. Barack Obama or Arizona Republican Sen. John McCain wins the presidential election, signs point to a more activist FDA in 2009

Adverse Events Reporting System Needs Immediate Upgrade – FDA Consultant

FDA should resume an abandoned plan for software acquisition and "immediately" begin the process of upgrading Center for Drug Evaluation and Research's Adverse Events Reporting System, a consultant hired by the agency recommends in a report that is highly critical of the center's efforts to create a second-generation AERS

Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch

One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel